Size of the round and participants
UK-based Isomorphic Labs has closed a $5 billion Series C funding round. Greenoaks and Sequoia Capital co-led the round. Alongside Alphabet, Andreessen Horowitz, Thrive Capital, GV and Temasek also participated. The company's total funding has now reached $7.7 billion.
Where the money goes
Isomorphic Labs will use the new capital to develop IsoDDE, its AI-powered drug design engine. The plans also include expanding into new biological areas and building the operational infrastructure needed to carry its first drug candidates into clinical trials.
The AlphaFold legacy
Founded in 2021 by Demis Hassabis, Isomorphic Labs draws on DeepMind's AlphaFold research. The IsoDDE engine designs new drug molecules and analyzes their properties in silico to produce candidates for different diseases. The company runs its own programs in cancer and immune system diseases and also has partnerships with drugmakers including Novartis, Eli Lilly and Johnson & Johnson.
The clinical trial threshold
The next step is to move its first drug candidates into clinical trials. That is a critical threshold for AI-designed molecules, marking the shift from lab and animal testing to human trials. Isomorphic Labs had also raised $2.1 billion last May.



